{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:28:25Z","timestamp":1778858905066,"version":"3.51.4"},"reference-count":125,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005026","name":"Belgian Foundation Against Cancer","doi-asserted-by":"publisher","award":["FA\/2014\/263"],"award-info":[{"award-number":["FA\/2014\/263"]}],"id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Research Foundation Flanders","doi-asserted-by":"crossref","award":["1510215N"],"award-info":[{"award-number":["1510215N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.ctrv.2015.09.006","type":"journal-article","created":{"date-parts":[[2015,9,30]],"date-time":"2015-09-30T04:55:27Z","timestamp":1443588927000},"page":"914-924","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Targeting immune checkpoints: New opportunity for mesothelioma treatment?"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3173-0500","authenticated-orcid":false,"given":"Elly","family":"Marcq","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Pauwels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan P.","family":"van Meerbeeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelien L.J.","family":"Smits","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ctrv.2015.09.006_b0005","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.critrevonc.2010.04.004","article-title":"Malignant pleural mesothelioma: the standard of care and challenges for future management","volume":"78","author":"van Meerbeeck","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"10.1016\/j.ctrv.2015.09.006_b0010","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2486\/indhealth.45.379","article-title":"Malignant mesothelioma: global incidence and relationship with asbestos","volume":"45","author":"Bianchi","year":"2007","journal-title":"Ind Health"},{"issue":"4\u20135","key":"10.1016\/j.ctrv.2015.09.006_b0015","first-page":"161","article-title":"Malignant mesothelioma in central and Eastern Europe","volume":"54","author":"Bianchi","year":"2000","journal-title":"Acta Med Croat"},{"issue":"15","key":"10.1016\/j.ctrv.2015.09.006_b0020","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMra050152","article-title":"Advances in malignant mesothelioma","volume":"353","author":"Robinson","year":"2005","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ctrv.2015.09.006_b0025","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11864-011-0149-1","article-title":"Novel targeted therapies and vaccination strategies for mesothelioma","volume":"12","author":"Bagia","year":"2011","journal-title":"Curr Treat Options Oncol"},{"issue":"14","key":"10.1016\/j.ctrv.2015.09.006_b0030","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1016\/j.ejca.2013.07.001","article-title":"Drug of the year: programmed death-1 receptor\/programmed death-1 ligand-1 receptor monoclonal antibodies","volume":"49","author":"Robert","year":"2013","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2015.09.006_b0035","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1165\/rcmb.2013-0472TR","article-title":"Immunotherapy for malignant pleural mesothelioma. Current status and future prospects","volume":"50","author":"Wong","year":"2014","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"2","key":"10.1016\/j.ctrv.2015.09.006_b0040","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ctrv.2015.09.006_b0045","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1158\/1078-0432.CCR-12-2625","article-title":"Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody","volume":"19","author":"Lipson","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"26","key":"10.1016\/j.ctrv.2015.09.006_b0050","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ctrv.2015.09.006_b0055","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ctrv.2015.09.006_b0060","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabro","year":"2013","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2015.09.006_b0065","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1084\/jem.190.3.355","volume":"190","author":"van","year":"1999","journal-title":"J Exp Med"},{"issue":"9","key":"10.1016\/j.ctrv.2015.09.006_b0070","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00262-014-1570-7","article-title":"Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy","volume":"63","author":"Pico de","year":"2014","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"10.1016\/j.ctrv.2015.09.006_b0075","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.4049\/jimmunol.165.10.5530","article-title":"Inhibition of IgG1 and IgE production by stimulation of the B cell CTLA-4 receptor","volume":"165","author":"Pioli","year":"2000","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.ctrv.2015.09.006_b0080","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1182\/blood-2002-06-1668","article-title":"CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells","volume":"101","author":"Pistillo","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ctrv.2015.09.006_b0085","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.0300-9475.2001.01019.x","article-title":"Expression of CTLA-4 by human monocytes","volume":"55","author":"Wang","year":"2002","journal-title":"Scand J Immunol"},{"issue":"6","key":"10.1016\/j.ctrv.2015.09.006_b0090","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2326","article-title":"Inhibitory B7-family molecules in the tumour microenvironment","volume":"8","author":"Zou","year":"2008","journal-title":"Nat Rev Immunol"},{"issue":"42","key":"10.1016\/j.ctrv.2015.09.006_b0095","doi-asserted-by":"crossref","first-page":"25107","DOI":"10.1074\/jbc.270.42.25107","article-title":"Cytotoxic T lymphocyte-associated molecule-4, a high-avidity receptor for CD80 and CD86, contains an intracellular localization motif in its cytoplasmic tail","volume":"270","author":"Leung","year":"1995","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.ctrv.2015.09.006_b0100","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1074-7613(00)80480-X","article-title":"Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement","volume":"4","author":"Linsley","year":"1996","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.ctrv.2015.09.006_b0105","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1046\/j.1365-3083.2001.00985.x","article-title":"Regulation of surface and intracellular expression of CTLA-4 on human peripheral T cells","volume":"54","author":"Wang","year":"2001","journal-title":"Scand J Immunol"},{"issue":"1","key":"10.1016\/j.ctrv.2015.09.006_b0110","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1177\/107327481402100112","article-title":"Update on immune checkpoint inhibitors in lung cancer","volume":"21","author":"Creelan","year":"2014","journal-title":"Cancer Control"},{"issue":"2","key":"10.1016\/j.ctrv.2015.09.006_b0115","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.lungcan.2012.04.011","article-title":"Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC)","volume":"77","author":"Erfani","year":"2012","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2015.09.006_b0120","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s002620050339","article-title":"Human ex vivo carcinoma cells produce transforming growth factor beta and thereby can inhibit lymphocyte functions in vitro","volume":"43","author":"Vanky","year":"1997","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"10.1016\/j.ctrv.2015.09.006_b0125","first-page":"1115","article-title":"TGF-beta 1 overexpression in breast cancer","volume":"3","author":"Christeli","year":"1996","journal-title":"Oncol Rep"},{"issue":"10","key":"10.1016\/j.ctrv.2015.09.006_b0130","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri1936","article-title":"Cancer despite immunosurveillance: immunoselection and immunosubversion","volume":"6","author":"Zitvogel","year":"2006","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"10.1016\/j.ctrv.2015.09.006_b0135","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1084\/jem.185.3.393","article-title":"CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics","volume":"185","author":"van der Merwe","year":"1997","journal-title":"J Exp Med"},{"issue":"7","key":"10.1016\/j.ctrv.2015.09.006_b0140","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1172\/JCI11710","article-title":"B7-dependent T-cell costimulation in mice lacking CD28 and CTLA4","volume":"107","author":"Mandelbrot","year":"2001","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.ctrv.2015.09.006_b0145","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1600-065X.2009.00770.x","article-title":"CD28 and CTLA-4 coreceptor expression and signal transduction","volume":"229","author":"Rudd","year":"2009","journal-title":"Immunol Rev"},{"issue":"8","key":"10.1016\/j.ctrv.2015.09.006_b0150","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/icb.2012.2","article-title":"Tumour eradication and induction of memory against murine mesothelioma by combined immunotherapy","volume":"90","author":"Kissick","year":"2012","journal-title":"Immunol Cell Biol"},{"issue":"3","key":"10.1016\/j.ctrv.2015.09.006_b0155","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.uct.2007.09.001","article-title":"Anti-CTLA4 antibody clinical trials in melanoma","volume":"2","author":"Ribas","year":"2007","journal-title":"Update Cancer Ther"},{"key":"10.1016\/j.ctrv.2015.09.006_b0160","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1479-5876-11-108","article-title":"The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-alpha production","volume":"11","author":"Laurent","year":"2013","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.ctrv.2015.09.006_b0165","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/2326-6066.CIR-13-0013","article-title":"Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells","volume":"1","author":"Selby","year":"2013","journal-title":"Cancer Immunol Res"},{"issue":"14","key":"10.1016\/j.ctrv.2015.09.006_b0170","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.09.006_b0175","article-title":"Mesothelioma treatment: are we on target?","author":"Hiddinga","year":"2014","journal-title":"J Adv Res"},{"issue":"4","key":"10.1016\/j.ctrv.2015.09.006_b0180","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"18","key":"10.1016\/j.ctrv.2015.09.006_b0185","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1093\/jnci\/djq310","article-title":"Improved endpoints for cancer immunotherapy trials","volume":"102","author":"Hoos","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.ctrv.2015.09.006_b0190","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ctrv.2015.09.006_b0195","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","article-title":"Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity","volume":"24","author":"Topalian","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.ctrv.2015.09.006_b0200","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol Rev"},{"issue":"3","key":"10.1016\/j.ctrv.2015.09.006_b0205","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1593\/neo.05733","article-title":"The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors","volume":"8","author":"Ghebeh","year":"2006","journal-title":"Neoplasia"},{"issue":"9","key":"10.1016\/j.ctrv.2015.09.006_b0210","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0611533104","article-title":"Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer","volume":"104","author":"Hamanishi","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.ctrv.2015.09.006_b0215","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1158\/1078-0432.CCR-06-2746","article-title":"Clinical significance and therapeutic potential of the programmed death-1 ligand\/programmed death-1 pathway in human pancreatic cancer","volume":"13","author":"Nomi","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.ctrv.2015.09.006_b0220","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1158\/1078-0432.CCR-04-1469","article-title":"Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer","volume":"11","author":"Ohigashi","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2015.09.006_b0225","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.immuni.2007.05.016","article-title":"Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses","volume":"27","author":"Butte","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.ctrv.2015.09.006_b0230","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/656340","article-title":"Programmed death ligand 2 in cancer-induced immune suppression","volume":"2012","author":"Rozali","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"3","key":"10.1016\/j.ctrv.2015.09.006_b0235","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0006-291X(03)01257-9","article-title":"Differential binding properties of B7-H1 and B7-DC to programmed death-1","volume":"307","author":"Youngnak","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"10.1016\/j.ctrv.2015.09.006_b0240","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1002\/eji.200526347","article-title":"PD-L2:PD-1 involvement in T cell proliferation, cytokine production, and integrin-mediated adhesion","volume":"35","author":"Saunders","year":"2005","journal-title":"Eur J Immunol"},{"issue":"1","key":"10.1016\/j.ctrv.2015.09.006_b0245","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.critrevonc.2013.08.002","article-title":"Targeting the PD1\/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities","volume":"89","author":"Merelli","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7077","key":"10.1016\/j.ctrv.2015.09.006_b0250","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ctrv.2015.09.006_b0255","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol"},{"issue":"8","key":"10.1016\/j.ctrv.2015.09.006_b0260","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.ctrv.2015.09.006_b0265","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1158\/0008-5472.CAN-05-4303","article-title":"Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up","volume":"66","author":"Thompson","year":"2006","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2015.09.006_b0270","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ijc.21775","article-title":"Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro","volume":"119","author":"Blank","year":"2006","journal-title":"Int J Cancer"},{"issue":"8","key":"10.1016\/j.ctrv.2015.09.006_b0275","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2008-09-179697","article-title":"Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression","volume":"114","author":"Mumprecht","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ctrv.2015.09.006_b0280","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1182\/blood-2009-03-206672","article-title":"PD-1\/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model","volume":"114","author":"Zhang","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ctrv.2015.09.006_b0285","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.molmed.2014.10.009","article-title":"Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway","volume":"21","author":"Ohaegbulam","year":"2015","journal-title":"Trends Mol Med"},{"issue":"13","key":"10.1016\/j.ctrv.2015.09.006_b0290","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J Exp Med"},{"issue":"22","key":"10.1016\/j.ctrv.2015.09.006_b0295","doi-asserted-by":"crossref","first-page":"7797","DOI":"10.1073\/pnas.0800928105","article-title":"T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR","volume":"105","author":"Sauer","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7528","key":"10.1016\/j.ctrv.2015.09.006_b0300","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.ctrv.2015.09.006_b0305","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1172\/JCI31184","article-title":"LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems","volume":"117","author":"Grosso","year":"2007","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.ctrv.2015.09.006_b0310","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.ctrv.2015.09.006_b0315","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients","volume":"207","author":"Fourcade","year":"2010","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.ctrv.2015.09.006_b0320","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2009.04.045","article-title":"Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma","volume":"137","author":"Gehring","year":"2009","journal-title":"Gastroenterology"},{"issue":"39","key":"10.1016\/j.ctrv.2015.09.006_b0325","doi-asserted-by":"crossref","first-page":"15016","DOI":"10.1073\/pnas.0801497105","article-title":"Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade","volume":"105","author":"Blackburn","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.ctrv.2015.09.006_b0330","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.4049\/jimmunol.0803245","article-title":"PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients","volume":"182","author":"Fourcade","year":"2009","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.ctrv.2015.09.006_b0335","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.4049\/jimmunol.1002050","article-title":"MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis","volume":"186","author":"Hemon","year":"2011","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.ctrv.2015.09.006_b0340","doi-asserted-by":"crossref","first-page":"5744","DOI":"10.1073\/pnas.94.11.5744","article-title":"Characterization of the major histocompatibility complex class II binding site on LAG-3 protein","volume":"94","author":"Huard","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ctrv.2015.09.006_b0345","first-page":"269","article-title":"LAG-3 in cancer immunotherapy","volume":"344","author":"Goldberg","year":"2011","journal-title":"Curr Top Microbiol Immunol"},{"issue":"9","key":"10.1016\/j.ctrv.2015.09.006_b0350","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.4049\/jimmunol.172.9.5450","article-title":"Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo","volume":"172","author":"Workman","year":"2004","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.ctrv.2015.09.006_b0355","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1365-2567.2005.02145.x","article-title":"The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells","volume":"115","author":"Macon-Lemaitre","year":"2005","journal-title":"Immunology"},{"issue":"2","key":"10.1016\/j.ctrv.2015.09.006_b0360","doi-asserted-by":"crossref","first-page":"688","DOI":"10.4049\/jimmunol.174.2.688","article-title":"Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223)","volume":"174","author":"Workman","year":"2005","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.ctrv.2015.09.006_b0365","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10637-012-9866-y","article-title":"A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma","volume":"31","author":"Wang-Gillam","year":"2013","journal-title":"Invest New Drugs"},{"issue":"19","key":"10.1016\/j.ctrv.2015.09.006_b0370","doi-asserted-by":"crossref","first-page":"6225","DOI":"10.1158\/1078-0432.CCR-09-0068","article-title":"A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma","volume":"15","author":"Brignone","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"6871","key":"10.1016\/j.ctrv.2015.09.006_b0375","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/415536a","article-title":"Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease","volume":"415","author":"Monney","year":"2002","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.ctrv.2015.09.006_b0380","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/ni1271","article-title":"The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity","volume":"6","author":"Zhu","year":"2005","journal-title":"Nat Immunol"},{"issue":"5853","key":"10.1016\/j.ctrv.2015.09.006_b0385","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1126\/science.1148536","article-title":"Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells","volume":"318","author":"Anderson","year":"2007","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.ctrv.2015.09.006_b0390","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-11-0096","article-title":"Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors","volume":"71","author":"Ngiow","year":"2011","journal-title":"Cancer Res"},{"issue":"17","key":"10.1016\/j.ctrv.2015.09.006_b0395","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1182\/blood-2010-10-310425","article-title":"Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia","volume":"117","author":"Zhou","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ctrv.2015.09.006_b0400","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/CJI.0b013e318183af0b","article-title":"Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients","volume":"31","author":"Fourcade","year":"2008","journal-title":"J Immunother"},{"issue":"10","key":"10.1016\/j.ctrv.2015.09.006_b0405","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1158\/1078-0432.CCR-07-4079","article-title":"Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies","volume":"14","author":"Berger","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1016\/j.ctrv.2015.09.006_b0410","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2015.09.006_b0415","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2015.09.006_b0420","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.3044","article-title":"Clinical and pharmacodynamic (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor","volume":"31","author":"Infante","year":"2013","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.ctrv.2015.09.006_b0425","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2015.09.006_b0430","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1479-5876-8-71","article-title":"First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity","volume":"8","author":"Brignone","year":"2010","journal-title":"J Transl Med"},{"issue":"7","key":"10.1016\/j.ctrv.2015.09.006_b0435","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/cncr.24899","article-title":"Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma","volume":"116","author":"Hino","year":"2010","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ctrv.2015.09.006_b0440","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1002\/cncr.25747","article-title":"Overall survival and PD-L1 expression in metastasized malignant melanoma","volume":"117","author":"Gadiot","year":"2011","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2015.09.006_b0445","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/labinvest.2013.130","article-title":"Programmed death ligand-1 expression in non-small cell lung cancer","volume":"94","author":"Velcheti","year":"2014","journal-title":"Lab Invest"},{"issue":"6","key":"10.1016\/j.ctrv.2015.09.006_b0450","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1177\/030089161209800612","article-title":"Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study","volume":"98","author":"Chen","year":"2012","journal-title":"Tumori"},{"issue":"6","key":"10.1016\/j.ctrv.2015.09.006_b0455","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-06-2599","article-title":"PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma","volume":"13","author":"Thompson","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2015.09.006_b0460","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.ctrv.2015.09.006_b0465","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1158\/0008-5472.CAN-14-3477","article-title":"Noninvasive imaging of tumor PD-L1 expression using radiolabeled anti-PD-L1 antibodies","volume":"75","author":"Heskamp","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2015.09.006_b0470","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/927240","article-title":"New roads open up for implementing immunotherapy in mesothelioma","volume":"2012","author":"Cornelissen","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"1","key":"10.1016\/j.ctrv.2015.09.006_b0475","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.canlet.2012.02.034","article-title":"Immunity and malignant mesothelioma: from mesothelial cell damage to tumor development and immune response-based therapies","volume":"322","author":"Izzi","year":"2012","journal-title":"Cancer Lett"},{"issue":"10","key":"10.1016\/j.ctrv.2015.09.006_b0480","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00262-010-0881-6","article-title":"CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection","volume":"59","author":"Yamada","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ctrv.2015.09.006_b0485","first-page":"1007","article-title":"Lymphocytic infiltration of pleural mesothelioma and its significance for survival","volume":"61","author":"Leigh","year":"1982","journal-title":"S Afr Med J"},{"issue":"4","key":"10.1016\/j.ctrv.2015.09.006_b0490","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jtcvs.2007.10.026","article-title":"Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma","volume":"135","author":"Anraku","year":"2008","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"5","key":"10.1016\/j.ctrv.2015.09.006_b0495","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1053\/ejso.2002.1294","article-title":"No relationship between tumour infiltrating lymphocytes and overall survival is seen in malignant mesothelioma of the pleura","volume":"28","author":"Mudhar","year":"2002","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2015.09.006_b0500","doi-asserted-by":"crossref","first-page":"e61895","DOI":"10.1371\/journal.pone.0061895","article-title":"Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity","volume":"8","author":"Lesterhuis","year":"2013","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.ctrv.2015.09.006_b0505","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1158\/1535-7163.MCT-11-1014","article-title":"CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma","volume":"11","author":"Wu","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.ctrv.2015.09.006_b0510","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.lungcan.2011.08.011","article-title":"Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey","volume":"75","author":"Zucali","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2015.09.006_b0515","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.7531","article-title":"A phase 2 single-arm study with tremelimumab at an optimized dosing schedule in second-line mesothelioma patients","volume":"32","author":"Calabro","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.09.006_b0520","article-title":"A randomized, double-blind study comparing tremelimumab to placebo in second and third line treatment of subjects with unresectable pleural or peritoneal mesothelioma","volume":"8","author":"Kindler","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2015.09.006_b0525","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.tps7609","article-title":"Randomized, double-blind, placebo-controlled study of tremelimumab for second and third-line treatment of unresectable pleural or peritoneal mesothelioma","volume":"32","author":"Maio","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2015.09.006_b0530","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2015.09.006_b0535","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"25","author":"Cedres","year":"2014","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2015.09.006_b0540","doi-asserted-by":"crossref","first-page":"e0121071","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Cedres","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2015.09.006_b0545","article-title":"PD-L1 expression in malignant mesothelioma: an immunohistochemical analysis of 33 cases","volume":"94","author":"Cowan","year":"2014","journal-title":"Lab Invest"},{"key":"10.1016\/j.ctrv.2015.09.006_b0550","doi-asserted-by":"crossref","unstructured":"Alley EW, Molife LR, Santoro A, Beckey K, Yuan S, Cheng JD, et al. Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: preliminary results from KEYNOTE-028. In: Proceedings of the 16th annual meeting of the American Association for Cancer Research, 18\u201322; 2015.","DOI":"10.1158\/1538-7445.AM2015-CT103"},{"issue":"6165","key":"10.1016\/j.ctrv.2015.09.006_b0555","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","article-title":"Breakthrough of the year 2013. Cancer immunotherapy","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.ctrv.2015.09.006_b0560","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3390\/vaccines3020420","article-title":"Integrating immune checkpoint blockade with anti-neo\/mutated antigens reactivity to increase the clinical outcome of immunotherapy","volume":"3","author":"Parmiani","year":"2015","journal-title":"Vaccines"},{"issue":"7463","key":"10.1016\/j.ctrv.2015.09.006_b0565","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.ctrv.2015.09.006_b0570","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1073\/pnas.0915174107","article-title":"PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors","volume":"107","author":"Curran","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"21","key":"10.1016\/j.ctrv.2015.09.006_b0575","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"issue":"5s","key":"10.1016\/j.ctrv.2015.09.006_b0580","article-title":"Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim phase I results","volume":"32","author":"Scott","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2015.09.006_b0585","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2015.09.006_b0590","doi-asserted-by":"crossref","first-page":"e30852","DOI":"10.1371\/journal.pone.0030852","article-title":"Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization","volume":"7","author":"Baitsch","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ctrv.2015.09.006_b0595","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrc1613","article-title":"Immunotherapy and chemotherapy \u2013 a practical partnership","volume":"5","author":"Lake","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"10.1016\/j.ctrv.2015.09.006_b0600","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1002\/cncr.23086","article-title":"Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies","volume":"110","author":"O\u2019Day","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2015.09.006_b0605","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/OTT.S4833","article-title":"CTLA-4 blockade: therapeutic potential in cancer treatments","volume":"3","author":"Tarhini","year":"2010","journal-title":"Onco Targets Ther"},{"issue":"32","key":"10.1016\/j.ctrv.2015.09.006_b0610","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.1200\/JCO.2008.17.8954","article-title":"Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment","volume":"26","author":"Fong","year":"2008","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2015.09.006_b0615","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1517\/14712598.7.8.1245","article-title":"Update on anti-CTLA-4 antibodies in clinical trials","volume":"7","author":"Langer","year":"2007","journal-title":"Expert Opin Biol Ther"},{"issue":"23","key":"10.1016\/j.ctrv.2015.09.006_b0620","first-page":"5301","article-title":"Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice","volume":"58","author":"Mokyr","year":"1998","journal-title":"Cancer Res"},{"issue":"5s","key":"10.1016\/j.ctrv.2015.09.006_b0625","article-title":"T-cell inflamed phenotype and PDL1 expression in malignant mesothelioma","volume":"32","author":"Kindler","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573721500170X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573721500170X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T00:58:19Z","timestamp":1599613099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030573721500170X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":125,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S030573721500170X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2015.09.006","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting immune checkpoints: New opportunity for mesothelioma treatment?","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2015.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}